Categories: DataDevelopmentDrugLearnPlatformTechnology
Raremark, is a real-world data collection platform focused on rare diseases, their technology helps rare disease companies identify, engage and learn from patients, dramatically improving data collection to inform drug development.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.10.2018 | - | $3.9M | - |
Mentions in press and media 6
| Date | Title | Description |
| 23.10.2018 | Term Sheet — Tuesday, October 23 | A CLASH OF VALUES
After staying awfully quiet, Softbank CEO Masayoshi Son finally made a move in the wake of the ongoing uproar over the disappearance of journalist Jamal Khashoggi. In a last-minute decision, Son decided to cancel his speak... |
| 23.10.2018 | Daily funding roundup - October 23th, 2018 | Raremark raised £4M; Synthetic Minds raised $5.5M; Ethic raised $6.8M; Finn AI raised $11M;
Raremark: Raremark is a free online service in rare disease, which makes scientific and medical knowledge accessible and understandable for patients... |
| 22.10.2018 | Raremark Raises £3m in Funding | Raremark, a London, UK-based rare disease patient-data platform, raised £3m in funding.
The round was led by AlbionVC and Ananda Ventures, with participation from Oltre Venture and existing major investor the Cass Entrepreneurship Fund.
The... |
| 22.10.2018 | Ananda Impact Ventures closes new €50 million fund to invest in 20 European impact startups | The Munich and London-based Ananda Impact Ventures team today announced they have secured €50 million in fresh capital for its third fund. In particular, positive exits and milestones achieved by the first two funds convinced investors that... |
| 22.10.2018 | Rare disease analytics platform Raremark raises $3.9M | |
| 21.10.2018 | Ananda Impact Ventures closes its third fund at €50 million, announces first five investments | Exclusive: Munich-based impact VC firm Ananda Impact Ventures has secured €50 million for its third fund, bringing the total amount under its management to €80 million across three funds. Among the limited partners of the new fund are the E... |
Reviews 0
